At 6,000 sq ft, this cyclotron radiochemistry facility serves as a manufacturing source of radiopharmaceuticals, which are used in positron emission tomography (PET) scans that provide vital clinical care and research information on illnesses such as cancer, dementia and cardiovascular diseases. Completed in May 2023, this cyclotron facility helps maintain the reliable supply of PET drugs for Utah and surrounding states.

Designed to meet all current regulatory requirements and prepare for future stricter standards, the facility required extensive planning through the architectural design team, engineering consultants and team scientists who visited multiple peer facilities to learn best practices. Initial design included painted concrete surfaces, but the client needed a surface better suited to cleaning. The team proposed using skim coating sheetrock mud over the concrete surface and painting it, resulting in a more user-friendly finish. Safety was critical given the project’s inclusion of radioactive materials. The team made extensive use of lead shielding and monitored each space and its exhaust pathways by using computer-controlled radiation area detection devices.